**Title:** Cost-Effectiveness of Screening for Asymptomatic Carotid Artery Stenosis Based on Atherosclerotic Cardiovascular Disease Risk Thresholds

**Authors:** Jinyi Zhu, PhD[*1]; Janice Jhang[*2]; Hanxuan Yu, MEd[1]; Alvin I Mushlin, MD, ScM[3]; Hooman Kamel, MD[4]; Nathaniel Alemayehu[5]; John Giardina, PhD[6]; Ajay Gupta, MD[7]; Ankur Pandya, PhD[2,5]

[*]Jinyi Zhu and Janice Jhang are co-first authors.

**Affiliations:**
[1]Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN, USA;
[2]Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, USA;
[3]Departments of Population Health Sciences and Medicine, Weill Cornell Medical College, New York, NY, USA;
[4]Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, New York, NY, USA;
[5]Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA;
[6]Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA;
[7]Department of Radiology, Weill Cornell Medicine, New York, NY, USA

**Address for correspondence:**
Jinyi Zhu, PhD
Department of Health Policy, Vanderbilt University School of Medicine, Nashville, TN 37203, USA
T: 615-875-6854
Email: jinyi.zhu.1@vanderbilt.edu

**Word count:** 3,596

**Abstract (Word count: 350 out of 350)**

**Background:** Carotid artery stenosis (50-99% extracranial internal carotid artery narrowing) is a risk factor for ischemic stroke. Yet, no population-based studies have directly assessed the benefits and harms of screening for asymptomatic carotid artery stenosis (ACAS). Given the variability in ACAS prevalence and stroke risk according to clinical factors, we sought to evaluate the cost-effectiveness of ACAS screening by cardiovascular risk-stratified subgroups.

**Methods:** We developed a microsimulation model of ACAS and stroke to project the lifetime costs and quality-adjusted life-years (QALYs) associated with ACAS screening, stratified by individuals' 10-year atherosclerotic cardiovascular disease (ASCVD) risk predicted from the pooled cohort equations. The model cohort was representative of US adults aged 50–80 years without history of stroke, constructed using sampling with replacement from the National Health and Nutrition Examination Survey. We used the Cardiovascular Health Study to estimate the severity of ACAS based on individual characteristics (e.g., age, sex, smoking status, blood pressure, and cholesterol). Stroke risks were functions of these characteristics and ACAS severity. In the model, individuals testing positive with Duplex ultrasound (>70% stenosis) and a confirmatory diagnostic test undergo revascularization, which reduces the risk of stroke but also introduces complication risks. Diagnostic performance parameters, revascularization benefits and risks, event rates associated with stroke, utility weights, and costs were estimated from published sources. Cost-effectiveness was assessed from the health care sector perspective using a $100,000/QALY threshold.

**Results**: We found that screening individuals with a 10-year ASCVD risk greater than 25% was the most cost-effective strategy, with an incremental cost-effectiveness ratio of $78,000/QALY. This strategy would make approximately 23% of the US adult population aged 50–80 years eligible for screening, averting an estimated 53,709 strokes. Results were sensitive to variations in key parameters, including the efficacy and complication risk of revascularization.

**Conclusions:** Although the US Preventive Services Task Force recommends against ACAS screening in the general population, a one-time screening may be cost-effective for adults with ASCVD risk >25%. Nonetheless, the cost-effectiveness of such screening is contingent on updated findings from ongoing research like the CREST-2 trial, which could reshape the understanding of revascularization's efficacy in contemporary medical practice.

## Introduction

Stroke is the 5th leading cause of mortality and a major cause of disability in the United States.[1] 14% of all strokes can be attributed to thromboembolism from previously asymptomatic stenosis of the extracranial internal carotid artery.[2] For some patients with carotid stenosis, a warning transient ischemic attack (TIA) will precede their stroke, and revascularization procedures are recommended for primary prevention of stroke in these patients.[2,3] For the remaining 11% of strokes attributable to undiagnosed carotid stenosis, population-level screening with duplex ultrasonography (DUS) could provide the opportunity for early intervention, but this approach is controversial in light of several evidence gaps in its effectiveness and risks.[2]

For patients with severe carotid artery stenosis, previous trials have found benefits associated with revascularization procedures such as carotid endarterectomy (CEA) and carotid artery stenting (CAS) for patients with severe carotid artery stenosis, but the procedures are also associated with complication risks.[4] With modern advancements in the medical management of stroke risk factors, e.g., utilization of anti-hypertensive and lipid-lowering medications, the optimal treatment for asymptomatic carotid artery stenosis (ACAS) remains unclear. The Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial (CREST-2) is currently underway to evaluate the risks and benefits associated with CEA and CAS compared to modern intensive medical management alone.[5]

The US Preventive Services Task Force (USPSTF) and most US professional societies currently recommend against screening for ACAS in the general adult population.[3,6–8] However, multiple professional societies recommend consideration of DUS screening for patients with multiple risk factors for stroke,[3,7,8] and evidence suggests a substantial volume of screenings is still being administered.[9–11]

Because several factors increase the risk for both carotid artery stenosis and ischemic stroke (e.g., older age, male sex, hypertension, current smoking, hypercholesterolemia, and diabetes mellitus),[1,3] a targeted screening for high-risk subgroups could reduce the number needed to screen to detect one case of ACAS and be potentially valuable. In its 2021 Evidence Review, the USPSTF highlighted the need to develop and validate tools to determine which individuals are at high risk for stroke due to carotid artery stenosis in order to better evaluate the benefits and harms of screening for ACAS.[6] To address this knowledge gap, we sought to evaluate the cost-effectiveness of a one-time, targeted screening of the US adult population for ACAS, stratified by subgroups based on atherosclerotic cardiovascular disease (ASCVD) risk, quantified using the American Heart Association's Pooled Cohort Equations (PCEs).[12]

## Methods

*Study Cohort*

We developed a microsimulation model of carotid artery stenosis and stroke for a hypothetical cohort representative of all US adults aged 50–80 years without prior TIA and stroke history (N = 100,473,000).[1] The model population was sampled by weights, with replacement, from the 2013-2014, 2015-2016, and 2017-2018 waves of the National Health and Nutrition Examination Survey (NHANES). We extracted individual-level characteristics — including age, sex, race, diabetes, smoking (current vs. any other), total and high-density lipoprotein cholesterol, systolic and diastolic blood pressure, history of ASCVD, and hypertension treatment — to construct the starting model cohort. Since carotid artery stenosis status was not collected in the NHANES, individuals were probabilistically assigned to one of the 5 starting carotid artery stenosis categories (<50%, 50–69%, 70–79%, 80–99%, or 100%).[13,14]

*Simulation Model*

The model tracks each individual's annual progression or regression of carotid artery stenosis, along with occurrences of TIA and stroke, while monitoring their health outcomes and associated costs over their lifetime. Pre-stroke natural history followed our previously published carotid stenosis model in terms of stenosis progression, regression, and revascularization, with new extensions related to ACAS screening and TIA.[15] Acute and post-acute stroke events and outcomes were based on another published stroke model that we previously developed and validated.[16] All individuals are subject to age- and sex-specific, non-stroke-related background mortality drawn from the US life tables.[17]

Each year, individuals in the 0–49% narrowing category may progress to a 50–69% stenosis state. Individuals with 50–99% stenosis can experience varying degrees of progression, advancing by one, two, or three categories, while regression is limited to a decrease of only one category annually. We assumed that patients with 100% stenosis have no chance of regression and are ineligible for revascularization. A higher stenosis severity is associated with an increased annual risk of TIA and stroke. Individuals' risk of TIA is based on their age, sex, and stenosis severity.[18] Any individual who experiences a TIA receives a confirmatory diagnostic test of computed tomography angiography or magnetic resonance angiography in the same year and undergoes revascularization if tested positive for carotid stenosis.

Once an individual develops a stroke event, they transition to our previously published acute and post-acute stroke model, where further details on the model's structure and parameter

inputs can be found.[16] In brief, patients' acute stroke outcomes are governed by the modified Rankin Scale (mRS, a discrete score between 0 and 6, where mRS = 0 indicates no symptoms and mRS = 6 indicates death). A more severe mRS is also associated with higher recurrent stroke risk, higher excess mortality, lower utility weights, and higher annual post-stroke management costs for stroke survivors.

*Model Parameterization*

We derived key parameters, including event rates, probabilities, test characteristics, intervention effects, utility weights, and costs, from several prospective cohort studies and existing literature (detailed in Table 1). Specifically, to probabilistically determine the presence of moderate-to-severe ACAS (>50% stenosis) for each individual at baseline, we first created a multivariate logistic regression model from the Cardiovascular Health Study (CHS), and then calibrated this model to the sex- and age-specific prevalence of ACAS from published sources.[13] The choice of predictors in this model was based on the ACAS prediction model proposed by de Weerd et al.[19], which was the best model found by Poorthuis et al.[20] in an external validation study of models proposed for predicting ACAS. Our prediction model included overlapping covariates available in NHANES, i.e., age, sex, race, diabetes, smoking, total and high-density lipoprotein cholesterol, systolic and diastolic blood pressure, and history of ASCVD. We validated this prediction model using a split sample approach (i.e., in a test set of 30% of the data). For individuals who were predicted to have stenosis >50%, we then randomly assigned them to 1 of the 4 stenosis blockage categories (50–69%, 70–79%, 80–99%, or 100%) with weights obtained through calibration to data reported in Hirt 2014.[14]

The risk of ischemic stroke was based on 10-year cumulative incidence functions developed by Ferket et al. using data from 3 population-based cohort studies (the CHS, the Atherosclerosis Risk in Communities Study, and the Rotterdam Study).[21] Ferket et al. cross-validated the ischemic stroke risk prediction function by fitting models in 2 cohorts and evaluating in the 3rd, resulting in c-statistics ranging from 0.651–0.760.[21] Factors used to predict individual risk of ischemic stroke included age, sex, race, current smoking status, diabetes, antihypertensive medication use, systolic blood pressure, and history of coronary heart disease.[21] To capture the longitudinal development of stroke risk, we utilized data from the CHS in a two-step approach: First, we predicted each individual's 10-year ischemic stroke risk at various observed time points, employing the equations by Ferket et al.[21] Subsequently, we applied a longitudinal regression model, relating this 10-year risk to follow-up time and the interaction between time and baseline stroke risk factors. Estimates from this longitudinal model were used in the simulation model to predict each individual's stroke risk over time. History of TIA, stenosis

severity, and history of revascularization affected individuals' stroke risk using separate relative risk estimates that were applied multiplicatively (Table 1).

*Screening Strategies*

In our model, a specific subset of individuals receives a one-time ACAS screening, the selection of which is dependent on the strategy being evaluated and each individual's risk of ASCVD. In addition to screening none and screening all, we evaluated six ACAS screening strategies that were stratified based on 10-year ASCVD risk thresholds: >30%, >25%, >20%, >15%, >10%, and >5%.[22] Individuals' 10-year ASCVD risks were predicted from the PCEs, using their age, sex, race, diabetes, smoking, total and high-density lipoprotein cholesterol, systolic blood pressure, and blood pressure treatment.

ACAS screening involves a DUS of carotid arteries first, followed by a confirmatory test of computed tomography angiography or magnetic resonance angiography if the DUS returns a positive result (70–99% stenosis in either carotid artery). If both tests confirm a 70–99% carotid artery stenosis, individuals then undergo a revascularization procedure (CEA or CAS), in line with the recommended guidelines for these interventions.[3,7] CEA and CAS are associated with complication risks (stroke or death).[23,24] After successful revascularization, individuals' level of stenosis is categorized as 0-49%, but they experience an elevated risk of stroke compared to those without a revascularization history in the same stenosis category. We assumed that revascularization, on average, reduces the incidence of non-perioperative stroke by 46% in our base case based on results from the Asymptomatic Carotid Surgery Trial (ACST-1),[4] and varied this assumption in our sensitivity analyses.

*Model Outcomes*

Our primary health outcomes were the number of strokes averted and quality-adjusted life-years (QALYs) gained. Quality of life was quantified using utility weights for post-TIA and post-stroke health states and a disutility weight for revascularization procedures (applied for 2 weeks). Total lifetime costs included the costs of TIA and acute and post-acute stroke care, costs of screening tests and revascularization, and usual health care costs for individuals without a history of stroke. Costs were assessed from the health care sector perspective and inflation-adjusted to 2023 US dollars. We calculated the incremental cost-effectiveness ratio (ICER) as the additional cost per QALY gained for screening strategies that were neither dominated (i.e., more expensive and less effective) nor dominant (i.e., less expensive and more effective). We used a base-case cost-effectiveness threshold of $100,000/QALY.[25] Future health and cost outcomes were discounted annually at 3%.[26]

*Sensitivity Analyses*

We performed a set of univariate sensitivity analyses, varying each model parameter between its 95% confidence intervals (or otherwise plausible ranges) while holding the other parameters constant. We also conducted a two-way sensitivity analysis on two key parameters with large uncertainty and evidence gap: the efficacy and complication risk of revascularization for individuals with ACAS.

In probabilistic sensitivity analyses, we varied model input values based on pre-specified probability distributions and estimated the probability of each strategy being cost-effective at various cost-effectiveness thresholds. The parameter ranges and distributions used in our sensitivity analyses are summarized in Table 1. We reported the mean estimates for each model outcome from 1,000 samples of parameter sets from the probabilistic sensitivity analysis as our base case results, alongside the 95% uncertainty intervals (UIs).

We performed all statistical analyses using R (version 4.2.2) and programmed the simulation model using the Rcpp package (version 1.0.10).

## Results

### *Model Validation*

Summary statistics of our model cohort, stratified by 10-year ASCVD risk subgroups, are presented in Appendix Table 1. An increased ASCVD risk was correlated with a higher proportion of men, older age, and greater prevalence of ACAS. We found acceptable discrimination in the ACAS prediction model we derived from CHS data, with a c-statistic of 0.72 in the test set, similar to the external validation results reported by Poorthuis et al. (c-statistic = 0.75).[20] Our calibrated age- and sex-stratified ACAS prevalence estimates were comparable to data reported in a meta-analysis of population-based studies (Appendix Table 2).[13]

### *Base-Case Results*

The mean values and 95% UIs of all population-level outcomes of each screening strategy are reported in Table 2, while individual-level results are shown in Appendix Table 3. A more lenient screening threshold (i.e., lower ASCVD risk threshold) would consistently result in higher total discounted lifetime costs. Meanwhile, the number of strokes averted would be maximized at a 10-year ASCVD risk threshold of >5%, and total discounted lifetime QALYs were maximized at a threshold of >15%. This non-monotonicity in health outcomes across screening thresholds can be explained by the dual effect of ACAS screening: it diagnoses more cases of moderate-to-severe ACAS for early intervention, but simultaneously increases complications due to a higher number of revascularization procedures.

Under our base-case $100,000/QALY cost-effectiveness threshold, the optimal strategy involved screening adults aged 50–80 years who have a 10-year ASCVD risk greater than 25%. This strategy yielded an ICER of $78,000/QALY (95% UI, $56,000–106,100/QALY). Under this screening strategy, 23.0% of the population was estimated to be eligible for ACAS screening, resulting in 53,709 (49,951–57,612) total strokes that would be averted over the lifetime of our model cohort.

### *Sensitivity Analyses*

Figure 2 illustrates the variations in the optimal screening strategy when each parameter is individually adjusted within its confidence interval or plausible range. Lower specificity of screening tests, lower stenosis progression rate, worse revascularization efficacy, higher revascularization complication rate, or higher probability of post-revascularization restenosis would result in a more stringent optimal screening threshold of 10-year ASCVD risk than our

base-case result (i.e., screening those with 10-year ASCVD risk >25%), corresponding to fewer individuals being screened. The optimal screening strategy did not change when we varied all the other model parameters to their plausible changes.

Figure 3 shows the two-way sensitivity analysis results, focusing on two key model parameters: the efficacy and complication risk of revascularization procedures. We found that ACAS screening would be less favorable when the probability of complications was higher, or the efficacy of revascularization was worse than our base-case assumptions. Nonetheless, it might remain cost-effective to adopt a higher ASCVD risk threshold for screening (i.e., screening those with 10-year ASCVD risk >30%).

The probabilistic sensitivity analysis results are shown in cost-effectiveness acceptability curves and frontier (Figure 4, Panel A), where we varied all parameters at the same time, taking 1,000 random draws from their pre-defined distributions. For a range of cost-effectiveness thresholds from $0–200,000 per QALY, the acceptability curves show the probabilities of each ASCVD risk-based strategy being cost-effective, while the frontier displays the cost-effective strategy on average. We found a large uncertainty of the optimal screening threshold at the base-case $100,000/QALY threshold: The optimal strategy on average — screening ASCVD risk >25% — had a probability of 30.5% being optimal across 1,000 parameter sets, whereas a higher (>30%) or lower (>20%) threshold was optimal in 27.5% or 28.7% of all model iterations, respectively. This uncertainty was largely driven by the uncertainty in the cost-effectiveness of screening for the 20–25% and 25–30% 10-year ASCVD risk groups (Figure 4, Panel B). Our analysis robustly showed that screening individuals in the >30% risk group would be cost-effective in 99.8% of the 1,000 iterations. Conversely, screening those in lower ASCVD risk groups (0–15%) was never cost-effective, as evidenced in 0.0% of the iterations.

## Discussion

Our model-based cost-effectiveness analysis of targeted screening strategies for ACAS showed that screening individuals with 10-year ASCVD risk greater than 25% would meet conventional standards for cost-effectiveness in the U.S. (<$100,000/QALY). Individuals eligible for screening would represent ~23% of the US population aged 50–80 years. Most of the gains in stroke prevention would come from the group with the highest ASCVD risk (>30%).

These results were sensitive to assumptions regarding the effectiveness and safety of revascularization procedures, carotid stenosis incidence and progression probabilities, and the specificity of tests used to screen for and diagnose carotid stenosis. Model parameters were based on results from the Carotid Revascularization Endarterectomy Versus Stent Trial (CREST) and the first and second Asymptomatic Carotid Surgery Trials (ACST-1 and ACST-2). These trials did not compare the efficacy of revascularization plus modern intensive medical management to medical management alone. It is thought that the benefits of revascularization are diminishing due to modern advancements and increasing utilization of anti-hypertensive and lipid-lowering medications.[27] To account for these factors, CREST-2 is currently underway to re-assess the relative benefit of revascularization compared to intensive medical management alone for asymptomatic carotid stenosis. Once CREST-2 concludes, the results from our analysis can help translate the trial results into cost-effective screening recommendations. Medication advancements and declining stroke incidence suggest that revascularization will likely be less effective than reported in previous trials, so the optimal screening strategy may shift to higher ASCVD risk thresholds or no screening at all.

Our study directly responds to a key need highlighted by the USPSTF in its 2021 Recommendation Statement.[6] The USPSTF currently recommends against screening asymptomatic individuals for carotid stenosis, and most specialty societies agree.[3,6–8] However, guidelines from the Society for Vascular Surgery[7] and joint guidelines from multiple professional societies[8] include exceptions for individuals with risk factors for stroke, which are present in nearly 1 in 3 US adults.[1] Previous US-based studies to assess the cost-effectiveness of screening for asymptomatic carotid stenosis were conducted prior to 2000 and did not stratify screening strategies by individual risk. Assuming the benefit of endarterectomy for asymptomatic patients reported by the Asymptomatic Carotid Atherosclerosis Study, prior studies found that a one-time screening could be cost-effective if implemented in populations with a high prevalence of carotid stenosis or if both screening and endarterectomy were performed in centers of excellence.[28–30] More recent studies have assessed the value of using tools, e.g., the Carotid Mortality Index[31] or ultrasound imaging to assess cerebrovascular reserve[15] and plaque echolucency,[32] to risk stratify patients already identified with ACAS who might benefit most

from revascularization. However, no modern studies have explicitly re-assessed the value of a population-level screening for asymptomatic carotid stenosis.

Various risk scores and tools have been proposed to identify individuals at high risk for asymptomatic carotid stenosis to allow for targeted screening.[20,33] For our analysis, we stratified screening strategies by 10-year ASCVD risk estimated by the Pooled Cohort Equations. Developed by the American College of Cardiology and the American Heart Association, the 10-year ASCVD risk assessment is commonly used in clinical practice to estimate patients' future risk of cardiovascular events and would be efficient to implement for potential ACAS screening decisions. Poorthuis et al. investigated the detection rate of ACAS through selective screening by 10-year ASCVD risk thresholds and found that the prevalence of ACAS increased over increasing ASCVD risk groups for both men and women.[34] Compared to a number needed to screen (NNS) of 64 if all participants were screened, selective screening of participants with ASCVD risk >20% reduced the NNS to 27 and identified 40% of all ACAS cases.[34] Poorthuis et al. demonstrated that selective screening of ACAS using ASCVD risk assessment could reduce the NNS compared to population-wide screening, and our analysis complements these findings by explicitly identifying the optimal ASCVD risk threshold for selective screening.

Recently, the American Heart Association introduced the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) risk prediction equations. These equations estimate 10- and 30-year risk of cardiovascular disease, incorporating factors like the cardiovascular-kidney-metabolic syndrome and considering social determinants of health, while omitting race as a risk factor.[35] Risk stratification for ACAS screening using the PREVENT equations rather than the Pooled Cohort Equations could be evaluated in future studies.

Our study has several limitations. First, the NHANES data used to construct the model population did not report individuals' carotid stenosis status or severity, so we developed a multivariate logistic regression model to probabilistically determine the presence of moderate-severe ACAS for each individual in our model. We validated our ACAS prediction model using a split sample approach and found acceptable but imperfect discrimination (c-statistic = 0.72). Our ACAS prediction model was based on the best model[19] determined by Poorthuis et al.[20] in an external validation study of proposed models to predict ACAS and included all overlapping covariates that were available in NHANES. Poorthuis et al. found that most models proposed for ACAS prediction have modest discrimination; however, these prediction models can reliably identify cohorts of individuals at high risk of carotid stenosis, which could substantially reduce the NNS to detect ACAS.[20] Second, the assumptions regarding the efficacy and risk associated with revascularization are based on estimates from previous trials that did not use modern intensive medical management as the baseline comparator. However, our sensitivity analyses

provide interpretable thresholds for the pending results of CREST-2 that may shift the optimal ASCVD risk-based screening strategy. Third, this analysis did not differentiate between types of revascularization procedures, i.e., carotid endarterectomy and carotid artery stenting, but CREST,[36] ACST-2,[24] and the Asymptomatic Carotid Trial[37] have reported comparable outcomes for both procedures among patients with asymptomatic carotid stenosis. Fourth, our study did not account for secular trends in population stroke risk over time.[38] Improvements in medical management of stroke risk factors may continue to reduce the risk of cardiovascular events among patients with asymptomatic carotid stenosis in the future, which may diminish the value of a population-level screening policy, but our sensitivity analyses capture this potential uncertainty as it relates to the efficacy of revascularization versus medical management. Finally, while our full simulation model has not been externally validated, key parts have been validated, including the previously published acute and post-acute stroke models[16] and split-sample validations of individual-level data analyses that parameterized key model inputs such as the individual-level prediction of moderate-to-severe carotid stenosis. As discussed above, our prediction model was based on the best ACAS prediction model identified in an external validation study.[20]

Based on our model results, neither a screen-none policy nor a screen-all policy would be cost-effective in preventing stroke among individuals with ACAS. Instead, it may be cost-effective to screen adults at higher risk of having a cardiovascular event over the next 10 years. With our current base-case assumptions, screening adults with ASCVD risk >25% would meet conventional cost-effectiveness standards, making ~23% of the US population aged 50–80 years eligible for screening. Our results were sensitive to key parameters that will be clarified pending the results of CREST-2, so they should be interpreted in the context of the trial findings to inform future cost-effective screening guidelines.

## Tables

Table 1: Parameter inputs

| Parameter | Base-Case value | Confidence interval | Probability distribution | Data source |
|---|---|---|---|---|
| ***ACAS*** | | | | |
| Prevalence of moderate-to-severe ACAS | Age- and sex-specific | | | de Weerd et al,[13] 2010 |
| Annual probability of stenosis progression | 0.052 | 0.034–0.070 | β | Hirt,[14] 2014; Kakkos et al,[29]2014 |
| Conditional probability of progression by 2+ categories | 0.207 | 0.175–0.241 | β | Hirt,[14] 2014 |
| Conditional probability of progression by 3 categories (given progression by 2+ categories) | 0.5 | 0.4–0.6 | β | Assumption |
| Annual probability of stenosis regression | 0.045 | 0.024–0.065 | β | Hirt,[14] 2014 |
| ***TIA and stroke*** | | | | |
| Average annual risk of TIA across stenosis categories | Age- and sex-specific | | | Lioutas et al,[18] 2021 |
| Average annual risk of stroke across stenosis categories | Based on individual risk factors | | | Ferket et al,[21] 2014 |
| Odds ratio of TIA/stroke for 50-69% vs. 0-49% stenosis | 1.4 | 0.9–2.2 | Log-normal | Howard et al,[40] 2021 |
| Odds ratio of TIA/stroke for 70-79% vs. 0-49% stenosis | 2.3 | 1.5–3.5 | Log-normal | Howard et al,[40] 2021 |
| Odds ratio of TIA/stroke for 80-99% vs. 0-49% stenosis | 3.2 | 2.1–4.9 | Log-normal | Howard et al,[40] 2021 |
| Rate ratio of TIA/stroke for 100% vs. 0-49% stenosis | 7.74 | 2.19–27.44 | Log-normal | Hirt,[14] 2014 |
| Rate ratio of TIA/stroke given stenosis regression | 0 | | | Kakkos,[39] 2014 |
| Hazard ratio of stroke for patients with history of TIA vs. no TIA | 4.4 | 3.47–5.57 | Log-normal | Lioutas et al,[18] 2021 |
| ***Screening tests and revascularization*** | | | | |
| DUS sensitivity for stenosis >70% | 0.86 | 0.84–0.89 | β | Nederkoorn et al,[41] 2003; Saxena et al,[42] 2019 |
| DUS specificity for stenosis >70% | 0.87 | 0.84–0.90 | β | Nederkoorn et al,[41] 2003; Saxena et al,[42] 2019 |
| Confirmatory CTA/MRA sensitivity | 0.95 | 0.92–0.97 | β | Nederkoorn et al,[41] 2003; Saxena et al,[42] 2019 |

| | | | | |
|---|---|---|---|---|
| Confirmatory CTA/MRA specificity | 0.9 | 0.86–0.93 | β | Nederkoorn et al,[41] 2003; Saxena et al,[42] 2019 |
| Relative risk of future stroke following revascularization | 0.54 | 0.50–0.90 | Log-normal | Halliday et al,[4] 2010 |
| Probability of complications during revascularization | 0.031 | 0.025–0.038 | β | Hill et al,[23] 2012; Halliday et al,[24] 2021 |
| Conditional probability of death | 0.113 | 0.091–0.136 | β | Hill et al,[23] 2012 |
| Conditional probability of ischemic stroke | 0.887 | 0.864–0.910 | β | Hill et al,[23] 2012 |
| Stroke severity mRS 0-1 | 0.354 | | | Levin et al,[43] 2019 |
| Stroke severity mRS 2-3 | 0.323 | | | Levin et al,[43] 2019 |
| Stroke severity mRS 4-5 | 0.323 | | | Levin et al,[43] 2019 |
| Probability of restenosis following revascularization (from 0-49%) | 0.03 | 0.01–0.04 | β | Lal et al,[44] 2012 |
| ***Costs (2023 USD)*** | | | | |
| Cost of DUS | $148 | $118–$178 | γ | Medicare Physician Fee Schedule,[45] 2023 |
| Cost of confirmatory CTA/MRA scan | $314 | $270–380 | γ | Medicare Physician Fee Schedule,[45] 2023 |
| Cost of treatment for TIA | $8,598 | $4,160–$16,642 | γ | Kamel et al,[46] 2012 |
| Cost of revascularization for ACAS | $11,307 | $9,046–$13,569 | γ | Obeid et al,[47] 2017 |
| Cost of revascularization following TIA | $19,608 | $15,689–$23,529 | γ | Obeid et al,[47] 2017 |
| ***Quality of life (utility weights)*** | | | | |
| Utility of ACAS | 1 | 0.836–1 | β | Tengs et al,[48] 2003 |
| Utility of TIA | 0.95 | 0.8–1 | β | Kamel et al,[46] 2012 |
| Utility of revascularization procedure (applied for 2 weeks) | 0.77 | 0.77–1 | β | Cohen et al,[49] 2012 |

Values and sources of acute and post-acute stroke parameters are the same as in our previously published stroke model (detailed in Zhu et al.[16], 2023).
ACAS = asymptomatic carotid artery stenosis. CTA = computed tomography angiography. DUS = bilateral Duplex ultrasound scan of carotid arteries. MRA = magnetic resonance angiography. mRS=modified Rankin scale.

Table 2: Base-case cost-effectiveness results

| | **Proportion of US population screened** | **Relative to screen none** | | | **Relative to subsequent lower-intensity screening strategy** | | |
|---|---|---|---|---|---|---|---|
| | | Number of strokes averted | Cost ($, in millions) | QALYs (in thousands) | Incremental Cost, ($, in millions) | Incremental QALYs (in thousands) | ICER ($/QALY) |
| Screen none | 0% | Reference | | | | | |
| Screen ASCVD risk >30% | 16.1% | 43,921 (41,035 to 46,860) | 4,239 (3,383 to 4,987) | 138.8 (125.5 to 152.4) | 4,239 (3,383 to 4,987) | 138.8 (125.5 to 152.4) | 31,000 (22,000 to 39,000) |
| Screen ASCVD risk >25% | 23.0% | 53,709 (49,951 to 57,612) | 6,469 (5,262 to 7,493) | 167.2 (149.2 to 186.2) | 2,230 (1,874 to 2,531) | 28.5 (23.8 to 33.7) | 78,000 (56,000 to 106,000) |
| Screen ASCVD risk >20% | 31.8% | 63,829 (58,929 to 68,897) | 9,463 (7,820 to 10,898) | 192.8 (168.5 to 218.2) | 2,994 (2,548 to 3,369) | 25.6 (19.2 to 32.8) | 117,000 (80,000 to 171,000) |
| Screen ASCVD risk >15% | 43.3% | 74,544 (68,471 to 81,116) | 13,545 (11,311 to 15,472) | 211.8 (179.9 to 247.1) | 4,083 (3,502 to 4,574) | 19.0 (11.2 to 28.6) | 215,000 (125,000 to 399,000) |
| Screen ASCVD risk >10% | 59.0% | 80,715 (73,331 to 89,242) | 19,600 (16,540 to 22,138) | 211.2 (169.3 to 259.4) | Dominated | | |
| Screen ASCVD risk >5% | 79.8% | 81,111 (72,335 to 91,808) | 28,093 (24,023 to 31,444) | 157.8 (103.2 to 223.4) | Dominated | | |
| Screen all | 100% | 75,768 (65,426 to 88,261) | 36,912 (31,661 to 41,212) | 76.4 (9.5 to 160.8) | Dominated | | |

All results are reported for the US adult population aged 50–80 years (total N = 100,473,000). Both costs and QALYs are discounted at 3% per year. Costs are reported in 2023 USD.

ASCVD = atherosclerotic cardiovascular disease. ICER = incremental cost-effectiveness ratio. QALY = quality-adjusted life-years.

**Figure Captions**

Figure 1: Model schematic. Individuals with no history of stroke can progress or regress in carotid artery stenosis severity. Severity of carotid artery stenosis affects individuals' probability of experiencing a transient ischemic attack (TIA) or stroke. Following a revascularization procedure, individuals are categorized as having 0–49% carotid artery stenosis.

Figure 2: One-way sensitivity analysis results. Stars denote the base-case parameter values. The graph displays the six parameters that significantly influenced the optimal screening strategy, as indicated by sensitivity to variations within these parameters. The optimal screening strategy did not change while varying any of the other model parameters. ASCVD = atherosclerotic cardiovascular disease. DUS = bilateral Duplex ultrasound scan of carotid arteries. MRA = magnetic resonance angiography. RR = relative risk.

Figure 3: Impact of revascularization complications and efficacy on the optimal screening strategy. This heat map represents the results of a two-way sensitivity analysis evaluating how variations in the probability of revascularization complications and the efficacy of revascularization affect the choice of optimal screening strategy. ASCVD = atherosclerotic cardiovascular disease.

Figure 4: Probabilistic sensitivity analysis results. Panel A shows the cost-effectiveness acceptability curves and frontier. Colored curves denote the cost-effectiveness acceptability curves, showing the probability of a strategy being optimal at different cost-effectiveness thresholds. Black circle crosses represent the cost-effectiveness acceptability frontier, showing the optimal strategy on average for a given cost-effectiveness threshold. Panel B shows the probability of ACAS screening being cost-effective for each 10-year ASCVD risk subgroup. ACAS = asymptomatic carotid artery stenosis. ASCVD = atherosclerotic cardiovascular disease.

Figure 1: Model schematic. Individuals with no history of stroke can progress or regress in carotid artery stenosis severity. Severity of carotid artery stenosis affects individuals' probability of experiencing a transient ischemic attack (TIA) or stroke. Following a revascularization procedure, individuals are categorized as having 0–49% carotid artery stenosis.



Figure 2: One-way sensitivity analysis results. Stars denote the base-case parameter values. The graph displays the six parameters that significantly influenced the optimal screening strategy, as indicated by sensitivity to variations within these parameters. The optimal screening strategy did not change while varying any of the other model parameters. ASCVD = atherosclerotic cardiovascular disease. DUS = bilateral Duplex ultrasound scan of carotid arteries. MRA = magnetic resonance angiography. RR = relative risk.



Figure 3: Impact of revascularization complications and efficacy on the optimal screening strategy. This heat map represents the results of a two-way sensitivity analysis evaluating how variations in the probability of revascularization complications and the efficacy of revascularization affect the choice of optimal screening strategy. ASCVD = atherosclerotic cardiovascular disease.



Figure 4: Probabilistic sensitivity analysis results. Panel A shows the cost-effectiveness acceptability curves and frontier. Colored curves denote the cost-effectiveness acceptability curves, showing the probability of a strategy being optimal at different cost-effectiveness thresholds. Black circle crosses represent the cost-effectiveness acceptability frontier, showing the optimal strategy on average for a given cost-effectiveness threshold. Panel B shows the probability of ACAS screening being cost-effective for each 10-year ASCVD risk subgroup. ACAS = asymptomatic carotid artery stenosis. ASCVD = atherosclerotic cardiovascular disease.



## References


1. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation 2023;147:e93–e621. doi:10.1161/CIR.0000000000001123.
2. Naylor AR. Why is the management of asymptomatic carotid disease so controversial? The Surgeon 2015;13:34–43. doi:10.1016/j.surge.2014.08.004.
3. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021;52:e364–e467. doi:10.1161/STR.0000000000000375.
4. Halliday A, Harrison M, Hayter E, Kong X, Mansfield A, Marro J, et al. 10-year stroke prevention after successful carotid endarterectomy for asymptomatic stenosis (ACST-1): a multicentre randomised trial. The Lancet 2010;376:1074–1084. doi:10.1016/S0140-6736(10)61197-X.
5. Mott M, Koroshetz W, Wright CB. CREST-2: Identifying the Best Method of Stroke Prevention for Carotid Artery Stenosis. Stroke 2017;48:e130–e131. doi:10.1161/STROKEAHA.117.016051.
6. US Preventive Services Task Force. Screening for Asymptomatic Carotid Artery Stenosis: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325:476–481. doi:10.1001/jama.2020.26988.
7. AbuRahma AF, Avgerinos ED, Chang RW, Darling RC, Duncan AA, Forbes TL, et al. Society for Vascular Surgery clinical practice guidelines for management of extracranial cerebrovascular disease. J Vasc Surg 2022;75:4S-22S. doi:10.1016/j.jvs.2021.04.073.
8. Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. Stroke 2011;42:e464-540. doi:10.1161/STR.0b013e3182112cc2.
9. Radomski TR, Zhao X, Lovelace EZ, Sileanu FE, Rose L, Schwartz AL, et al. Use and Cost of Low-Value Health Services Delivered or Paid for by the Veterans Health Administration. JAMA Intern Med 2022;182:832–839. doi:10.1001/jamainternmed.2022.2482.
10. Anderson TS, Leonard S, Zhang AJ, Madden E, Mowery D, Chapman WW, et al. Trends in Low-Value Carotid Imaging in the Veterans Health Administration From 2007 to 2016. JAMA Netw Open 2020;3:e2015250. doi:10.1001/jamanetworkopen.2020.15250.
11. Boudreau E, Schwartz R, Schwartz AL, Navathe AS, Caplan A, Li Y, et al. Comparison of Low-Value Services Among Medicare Advantage and Traditional Medicare Beneficiaries. JAMA Health Forum 2022;3:e222935. doi:10.1001/jamahealthforum.2022.2935.
12. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation 2014;129:S49–S73. doi:10.1161/01.cir.0000437741.48606.98.
13. de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41:1294–1297. doi:10.1161/STROKEAHA.110.581058.
14. Hirt LS. Progression rate and ipsilateral neurological events in asymptomatic carotid stenosis. Stroke 2014;45:702–706. doi:10.1161/STROKEAHA.111.613711.
15. Pandya A, Gupta A, Kamel H, Navi BB, Sanelli PC, Schackman BR. Carotid Artery Stenosis: Cost-effectiveness of Assessment of Cerebrovascular Reserve to Guide Treatment of Asymptomatic Patients. Radiology 2015;274:455–463. doi:10.1148/radiol.14140501.
16. Zhu J, Kamel H, Gupta A, Mushlin AI, Menzies NA, Gaziano TA, et al. Prioritizing Quality

Measures in Acute Stroke Care : A Cost-Effectiveness Analysis. Ann Intern Med 2023;176:649–657. doi:10.7326/M22-3186.
17. Arias E, Xu J. United States Life Tables, 2018. Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst 2020;69:1–45.
18. Lioutas V-A, Ivan CS, Himali JJ, Aparicio HJ, Leveille T, Romero JR, et al. Incidence of Transient Ischemic Attack and Association With Long-term Risk of Stroke. JAMA 2021;325:373–381. doi:10.1001/jama.2020.25071.
19. de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, et al. Prediction of asymptomatic carotid artery stenosis in the general population: identification of high-risk groups. Stroke 2014;45:2366–2371. doi:10.1161/STROKEAHA.114.005145.
20. Poorthuis MHF, Halliday A, Massa MS, Sherliker P, Clack R, Morris DR, et al. Validation of Risk Prediction Models to Detect Asymptomatic Carotid Stenosis. J Am Heart Assoc 2020;9:e014766. doi:10.1161/JAHA.119.014766.
21. Ferket BS, Kempen BJH van, Wieberdink RG, Steyerberg EW, Koudstaal PJ, Hofman A, et al. Separate prediction of intracerebral hemorrhage and ischemic stroke. Neurology 2014;82:1804–1812. doi:10.1212/WNL.0000000000000427.
22. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2935–2959. doi:10.1016/j.jacc.2013.11.005.
23. Hill MD, Brooks W, Mackey A, Clark WM, Meschia JF, Morrish WF, et al. Stroke after carotid stenting and endarterectomy in the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST). Circulation 2012;126:3054–3061. doi:10.1161/CIRCULATIONAHA.112.120030.
24. Halliday A, Bulbulia R, Bonati LH, Chester J, Cradduck-Bamford A, Peto R, et al. Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy. The Lancet 2021;398:1065–1073. doi:10.1016/S0140-6736(21)01910-3.
25. Neumann PJ, Cohen JT, Weinstein MC. Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold. N Engl J Med 2014;371:796–797. doi:10.1056/NEJMp1405158.
26. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. JAMA 2016;316:1093–1103. doi:10.1001/jama.2016.12195.
27. Matyori A, Brown CP, Ali A, Sherbeny F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC/AHA guidelines. Saudi Pharm J SPJ 2023;31:795–800. doi:10.1016/j.jsps.2023.04.002.
28. Derdeyn CP, Powers WJ. Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease. Stroke 1996;27:1944–1950. doi:10.1161/01.str.27.11.1944.
29. Lee TT, Solomon NA, Heidenreich PA, Oehlert J, Garber AM. Cost-Effectiveness of Screening for Carotid Stenosis in Asymptomatic Persons. Ann Intern Med 1997;126:337–346. doi:10.7326/0003-4819-126-5-199703010-00001.
30. Yin D, Carpenter JP. Cost-effectiveness of screening for asymptomatic carotid stenosis. J Vasc Surg 1998;27:245–255. doi:10.1016/s0741-5214(98)70355-6.
31. Keyhani S, Madden E, Cheng EM, Bravata DM, Halm E, Austin PC, et al. Risk Prediction Tools to Improve Patient Selection for Carotid Endarterectomy Among Patients With Asymptomatic Carotid Stenosis. JAMA Surg 2019;154:336–344. doi:10.1001/jamasurg.2018.5119.
32. Baradaran H, Gupta A, Anzai Y, Mushlin AI, Kamel H, Pandya A. Cost Effectiveness of Assessing Ultrasound Plaque Characteristics to Risk Stratify Asymptomatic Patients With

Carotid Stenosis. J Am Heart Assoc 2019;8:e012739. doi:10.1161/JAHA.119.012739.
33. Poorthuis MHF, Sherliker P, Morris DR, Massa MS, Clarke R, Staplin N, et al. Development and Internal Validation of a Risk Score to Detect Asymptomatic Carotid Stenosis. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg 2021;61:365–373. doi:10.1016/j.ejvs.2020.11.029.
34. Poorthuis MHF, Sherliker P, de Borst GJ, Clack R, Lewington S, Clarke R, et al. Detection rates of asymptomatic carotid artery stenosis and atrial fibrillation by selective screening of patients without cardiovascular disease. Int J Cardiol 2023;391:131262. doi:10.1016/j.ijcard.2023.131262.
35. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation n.d.;0. doi:10.1161/CIR.0000000000001191.
36. Brott TG, Hobson RW, Howard G, Roubin GS, Clark WM, Brooks W, et al. Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis. N Engl J Med 2010;363:11–23. doi:10.1056/NEJMoa0912321.
37. Rosenfield K, Matsumura JS, Chaturvedi S, Riles T, Ansel GM, Metzger DC, et al. Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. N Engl J Med 2016;374:1011–1020. doi:10.1056/NEJMoa1515706.
38. Hackam DG. Optimal Medical Management of Asymptomatic Carotid Stenosis. Stroke 2021;52:2191–2198. doi:10.1161/STROKEAHA.120.033994.
39. Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, et al. Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg 2014;59:956-967.e1. doi:10.1016/j.jvs.2013.10.073.
40. Howard DPJ, Gaziano L, Rothwell PM, Oxford Vascular Study. Risk of stroke in relation to degree of asymptomatic carotid stenosis: a population-based cohort study, systematic review, and meta-analysis. Lancet Neurol 2021;20:193–202. doi:10.1016/S1474-4422(20)30484-1.
41. Nederkoorn PJ, van der Graaf Y, Hunink MGM. Duplex ultrasound and magnetic resonance angiography compared with digital subtraction angiography in carotid artery stenosis: a systematic review. Stroke 2003;34:1324–1332. doi:10.1161/01.STR.0000068367.08991.A2.
42. Saxena A, Ng EYK, Lim ST. Imaging modalities to diagnose carotid artery stenosis: progress and prospect. Biomed Eng OnLine 2019;18:66. doi:10.1186/s12938-019-0685-7.
43. Levin SR, Farber A, Cheng TW, Jones DW, Rybin D, Kalish JA, et al. Most patients experiencing 30-day postoperative stroke after carotid endarterectomy will initially experience disability. J Vasc Surg 2019;70:1499-1505.e1. doi:10.1016/j.jvs.2019.02.035.
44. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, et al. Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. Lancet Neurol 2012;11:755–763. doi:10.1016/S1474-4422(12)70159-X.
45. Search the Physician Fee Schedule | CMS n.d. https://www.cms.gov/medicare/physician-fee-schedule/search (accessed December 7, 2023).
46. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2012;43:881–883. doi:10.1161/STROKEAHA.111.641027.
47. Obeid T, Alshaikh H, Nejim B, Arhuidese I, Locham S, Malas M. Fixed and variable cost of carotid endarterectomy and stenting in the United States: A comparative study. J Vasc Surg 2017;65:1398-1406.e1. doi:10.1016/j.jvs.2016.11.062.
48. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. PharmacoEconomics 2003;21:191–200. doi:10.2165/00019053-200321030-00004.
49. Cohen DJ, Lavelle TA, Van Hout B, Li H, Lei Y, Robertus K, et al. Economic outcomes of percutaneous coronary intervention with drug-eluting stents versus bypass surgery for

patients with left main or three-vessel coronary artery disease: one-year results from the SYNTAX trial. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv 2012;79:198–209. doi:10.1002/ccd.23147.

Appendix Table 1. Summary statistics of the microsimulation model cohort, stratified by 10-year ASCVD risks

| **10-year ASCVD Risk** | **Sex (%Men)** | **Mean Age (SD)** | **ACAS Prevalence** | **% US Population aged 50-80 years** |
|---|---|---|---|---|
| 0–5% | 16.4% | 55.6 (4.1) | 0.28% | 20.2% |
| 5–10% | 42.4% | 59.6 (5.4) | 0.85% | 20.8% |
| 10–15% | 50.4% | 63.5 (6.0) | 1.9% | 15.7% |
| 15–20% | 54.6% | 65.5 (6.5) | 2.8% | 11.5% |
| 20–25% | 60.1% | 68.0 (6.3) | 4.0% | 8.73% |
| 25–30% | 66.7% | 69.5 (6.0) | 4.5% | 6.91% |
| >30% | 66.8% | 71.8 (5.7) | 7.1% | 16.1% |

Appendix Table 2. Age- and sex-stratified prevalence of asymptomatic carotid artery stenosis >50%, estimates from a meta-analysis of population-based studies (de Weerd et al., 2010[1]) vs. our calibrated prediction model estimates

| Age (Years) | de Weerd et al., 2010 | Calibrated Model Estimates |
|---|---|---|
| *Men* | | |
| 50-59 | 0.7% | 0.9% |
| 60-69 | 2.3% | 2.1% |
| 70-79 | 6.0% | 5.4% |
| *Women* | | |
| 50-59 | 0.5% | 0.7% |
| 60-69 | 2.0% | 2.8% |
| 70-79 | 3.6% | 5.6% |

1. de Weerd M, Greving JP, Hedblad B, Lorenz MW, Mathiesen EB, O'Leary DH, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010;41:1294–1297. doi:10.1161/STROKEAHA.110.581058.

Appendix Table 3: Base-case individual-level (i.e., per-person) results

| | **Undiscounted lifetime cost** | **Discounted lifetime cost** | **Undiscounted LE** | **Discounted LE** | **Undiscounted QALE** | **Discounted QALE** | **Total lifetime risk of stroke** |
|---|---|---|---|---|---|---|---|
| Screen none | 312,911<br>(312,655 to 313,155) | 217,139<br>(217,031 to 217,242) | 20.6926<br>(20.6652 to 20.7272) | 14.6715<br>(14.6581 to 14.6885) | 20.0021<br>(19.9771 to 20.0332) | 14.2757<br>(14.2627 to 14.2915) | 0.2023<br>(0.2009 to 0.2035) |
| Screen ASCVD risk >30% | 312,935<br>(312,677 to 313,182) | 217,182<br>(217,076 to 217,289) | 20.6934<br>(20.666 to 20.7279) | 14.6720<br>(14.6585 to 14.6890) | 20.0042<br>(19.9793 to 20.0352) | 14.2770<br>(14.2640 to 14.2928) | 0.2019<br>(0.2005 to 0.2030) |
| Screen ASCVD risk >25% | 312,952<br>(312,696 to 313,203) | 217,204<br>(217096 to 217,312) | 20.6936<br>(20.6662 to 20.7281) | 14.6721<br>(14.6586 to 14.6891) | 20.0047<br>(19.9799 to 20.0357) | 14.2773<br>(14.2644 to 14.293) | 0.2018<br>(0.2004 to 0.2029) |
| Screen ASCVD risk >20% | 312,976<br>(312,720 to 313,228) | 217,234<br>(217,123 to 217,342) | 20.6938<br>(20.6664 to 20.7284) | 14.6722<br>(14.6587 to 14.6892) | 20.0052<br>(19.9803 to 20.0360) | 14.2776<br>(14.2647 to 14.2932) | 0.2017<br>(0.2003 to 0.2028) |
| Screen ASCVD risk >15% | 313,010<br>(312,750 to 313,265) | 217,274<br>(217,167 to 217,384) | 20.6940<br>(20.6665 to 20.7286) | 14.6723<br>(14.6588 to 14.6892) | 20.0057<br>(19.9807 to 20.0365) | 14.2778<br>(14.2648 to 14.2935) | 0.2016<br>(0.2002 to 0.2027) |
| Screen ASCVD risk >10% | 313,066<br>(312,801 to 313,325) | 217,335<br>(217,224 to 217,447) | 20.6941<br>(20.6667 to 20.7287) | 14.6723<br>(14.6589 to 14.6893) | 20.0059<br>(19.9807 to 20.0367) | 14.2778<br>(14.2646 to 14.2937) | 0.2015<br>(0.2001 to 0.2026) |
| Screen ASCVD risk >5% | 313,150<br>(312,879 to 313,413) | 217,419<br>(217,304 to 217,534) | 20.6939<br>(20.6663 to 20.7285) | 14.6721<br>(14.6587 to 14.6892) | 20.0053<br>(19.9796 to 20.0364) | 14.2772<br>(14.2641 to 14.2932) | 0.2015<br>(0.2001 to 0.2027) |
| Screen all | 313,245<br>(312,966 to 313,517) | 217,507<br>(217,386 to 217,621) | 20.6934<br>(20.6658 to 20.7281) | 14.6719<br>(14.6584 to 14.6890) | 20.0040<br>(19.9782 to 20.0353) | 14.2764<br>(14.2634 to 14.2925) | 0.2015<br>(0.2002 to 0.2027) |

LE = life expectancy. QALE = Quality-adjusted life expectancy